| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Credit > Credit Cards and Minimum Payments - Living in Debt |
|
Advice You - Credit Cards and Minimum Payments - Living in Debt
Many people love their credit cards. It’s a fact of life and the figures bare this up. If you look at the ra According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product te at which UK credit card debt is rising it is quite amazing. Millions are being spent all day every day in ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in an endless frenzy of spending. Pretty soon, three quarters of all adults in the UK will have credit cards a lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. d if you were to ask any of them to give theirs up, you can bet their answer would be no. The convenience an here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe d security of carrying a credit card is so great that once people experience it, they rarely go back. One o d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro the favourite features of credit cards for many people is the minimum repayment option. This is usually in ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc the region of five pounds or two per cent. This means that even if you spend a thousand pounds on a shopping easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi spree, your bill at the end of the month could be as low as twenty pounds if you choose to make the minimum nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically payment. And this is what people do. It is what credit card providers want you to do, as it is how they mana and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ge to rake in billions in profits every year. If you do have a significant outstanding balance, then making ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi the minimum repayment is one of the most dangerous habits you can get into. Most minimum payments will barel ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a y cover the interest and finance charges that are due on the balance. This means that you are really just se dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod rvicing the debt. This is what many third world countries are forced to do with their national debts and mos cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin people do not want to be the personal equivalent of sub-Saharan Africa do they? Servicing debt means you pa tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen y the interest due, but pay nothing against the principal debt. So all those monthly payments that you make t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel re doing absolutely nothing to reduce the amount you owe. If you continue spending on the credit card, the ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust minimum amount, required simply to service the debt, will grow and grow each month. And all the while you ar y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products e paying back nothing. If you aspire to becoming debt free, then you really have to pay a good deal more tha . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de the minimum payment level. Also, if you are serious about clearing your credit card debt, but recognise tha elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip t it is going to take you more than just a couple of months, you may wish to consider consolidating the debt tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Greylisting - Yet Another Reason Why Emails To Your Customers Are Not Getting Through
|